Incretin-Based Therapies for the Treatment of Type 2 Diabetes: Evaluation of the Risks and Benefits
Open accessThe DOI matches its Crossref record; 39 of the 40 references it cites were found in a registry or an index.
Abstract
T ype 2 diabetes is a complex meta-bolic disorder characterized byhyperglycemia arising from a com-bination of insufficient insulin secretion together with resistance to insulin action. The incidence and prevalence of type 2 diabetes are rising steadily, fuelled in part by a concomitant increase in the world-wide rates of obesity. As longitudinal studies of type 2 diabetes provide evi-dence linking improved glycemic control with a reduction in the rates of diabetes-associated complications, there is consid-erable interest in the therapy of type 2 diabetes (Fig. 1), with a focus on the de-velopment and use of new agents that ex-hibit improved efficacy and safety relative
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Additionally, it was implicated that GLP-1 analogue therapy increased the risk of acute pancreatitis, but subsequent studies using larger cohorts did not confirm this finding.8,267”
From A review of current trends with type 2 diabetes epidemiology, aetiology, pathogenesis, treatments and future perspectives (2021) · cites this paper as [267]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
Self-citationNathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
Self-citationThe biology of incretin hormones
Drucker, D. J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.004 · Cited by 2,210
Self-citationBuse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503 · cited 4×
“Moreover, both exenatide and liraglutide reduce blood pressure, body weight, and plasma lipid profiles in subjects with type 2 diabetes (13), raising the hope that longterm treatment with these agents may reduce the incidence of cardiovascular events.”
BackgroundInfluentialSelf-citationLaboratory Support for the Diagnosis and Monitoring of Thyroid Disease
(2003) · Thyroid · doi:10.1089/105072503321086962 · Cited by 1,212
Nathan, D. M., Buse, J. B., Davidson, M. B., Heine, R. J., Holman, R. R., Sherwin, R., & Zinman, B. (2006) · Diabetes Care · doi:10.2337/dc06-9912 · Cited by 1,203
Self-citationDrucker, D. J., Buse, J. B., Taylor, K., Kendall, D. M., Trautmann, M., Zhuang, D., & Porter, L. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61206-4 · Cited by 1,070
Self-citationOral Antihyperglycemic Therapy for Type 2 Diabetes: Scientific Review
Inzucchi, S. E. (2002) · JAMA · doi:10.1001/jama.287.3.360 · Cited by 1,065
Ban, K., Noyan-Ashraf, M. H., Hoefer, J., Bolz, S.-S., Drucker, D. J., & Husain, M. (2008) · Circulation · doi:10.1161/circulationaha.107.739938 · Cited by 1,057 · cited 1×
“Intriguingly, the GLP-1 metabolite, GLP-1 (9–36), also exerts cardioprotective actions in preclinical studies through mechanisms independent of the known GLP-1R (14); hence, ongoing research is directed at understanding the complexity of incretin biology in the cardiovascular system and the potential for incretin-base…”
BackgroundSelf-citationNikolaidis, L. A., Mankad, S., Sokos, G. G., Miske, G., Shah, A., Elahi, D., & Shannon, R. P. (2004) · Circulation · doi:10.1161/01.cir.0000120505.91348.58 · Cited by 901
Research works printed but not linked: 2
- Horner, SEER Cancer Statistics Review, 1975–2006 [Internet], 2009
- Parola, 2009, FDA Advisory Committee Nonclinical Briefing Document, NDA, 22
Cited by
Items 201–300 of 321
Moshrefi, M., Yari, N., Nabipour, F., Bazrafshani, M. R., & Nematollahi‐Mahani, S. N. (2015) · Tissue and Cell · doi:10.1016/j.tice.2015.04.008 · Cited by 8
Hypoglycaemia in Type 2 Diabetes and in Elderly People
Zammitt, N. N., & Frier, B. M. (2013) · Wiley eBooks · doi:10.1002/9781118695432.ch12 · Cited by 9
Current Issues in Glp-1 Receptor Agonist Therapy for Type 2 Diabetes
Bloomgarden, Z. T., Blonde, L., Garber, A. J., & Wysham, C. (2012) · Endocrine Practice · doi:10.4158/ep12300.ra · Cited by 7
Incretin-Based Therapy for Type 2 Diabetes Mellitus: Pancreatic and Extrapancreatic Effects
Hartman, I., Rojas, E., & Rodríguez-Molina, D. (2013) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e318235f27d · Cited by 8
Wu, S., Zhang, C.-C., Chen, J., Zhang, X., Guan, M., & Geng, C. (2022) · Fitoterapia · doi:10.1016/j.fitote.2022.105336 · Cited by 7
Malloy, J. L., Meloni, A. R., & Han, J. (2013) · Postgraduate Medicine · doi:10.3810/pgm.2013.05.2661 · Cited by 8
Tanaka, K., Okada, Y., Mori, H., Miyazaki, M., Kuno, F., Sonoda, S., Sugai, K., Hajime, M., Kurozumi, A., Narisawa, M., et al. (2016) · Endocrine Journal · doi:10.1507/endocrj.ej16-0341 · Cited by 7
Humaida, S., Manzalji, K., Seyam, N. I., & Masalmani, L. A. (2025) · Cureus · doi:10.7759/cureus.85123 · Cited by 8
Guo, P., Zeng, M., Zhang, Y., Zhang, Z., Wu, Y., Ye, K., Chang, F., Wang, Y., Zheng, X., & Feng, W. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117546 · Cited by 6
Iványi, T., Fövényi, J., Faludi, P., Han, J., MacConell, L., Wille, S. A., & Kiljanski, J. I. (2012) · Clinical Therapeutics · doi:10.1016/j.clinthera.2012.04.022 · Cited by 6
Dipeptidyl Peptidase-4 Inhibitors in Diverse Patient Populations With Type 2 Diabetes
Hinnen, D. A. (2015) · The Science of Diabetes Self-Management and Care · doi:10.1177/0145721715609420 · Cited by 6
Alogliptin for the treatment of type 2 diabetes: a drug safety evaluation
Yabe, D., & Seino, Y. (2015) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2016.1125467 · Cited by 6
Uncertainties around incretin-based therapies: A literature review
Tulaihi, B. A., & Alhabib, S. M. (2015) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2015.06.009 · Cited by 7
Ye, X., Qi, J., Wu, Q., Yu, D., Li, S., Wu, Y., & Li, D. (2016) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2016.04.025 · Cited by 6
Glucagon-like peptide-1 agonists
Padwal, R. S. (2012) · BMJ · doi:10.1136/bmj.d7282 · Cited by 6
Diabetes and its Silent Partner: A Critical Review of Hyperinsulinemia and its Complications
Rangraze, I. R., El‐Tanani, M., Rabbani, S. A., Babiker, R. A., Matalka, I. I., & Rizzo, M. (2024) · Current Diabetes Reviews · doi:10.2174/0115733998311738240813110032 · Cited by 6
Incorporating glucagon-like peptide-1 receptor agonists into clinical practice.
Spellman, C. (2012) · PubMed · Cited by 5
Mamontova, E. D., Michurina, S. S., Stafeev, I., Sorkina, E., Sklyanik, I. A., Koksharova, E., Menshikov, M. Y., Shestakova, M. V., & Parfyonova, Y. V. (2021) · Biochemistry (Moscow) · doi:10.1134/s000629792103010x · Cited by 5
Tibaldi, J. M. (2014) · The American Journal of the Medical Sciences · doi:10.1097/maj.0000000000000202 · Cited by 5
Optimal Glycemic Control in the Elderly: Where is the Evidence and Who Should Be Targeted?
Tessier, D. (2011) · Aging Health · doi:10.2217/ahe.10.86 · Cited by 5
Clinical experience with exenatide in obese North Indian patients with type 2 diabetes mellitus
Bawa, T., Dhingra, V., Malhotra, N., Wasir, J. S., & Mithal, A. (2013) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.107804 · Cited by 5
Setji, T. L., & Feinglos, M. N. (2013) · Expert Review of Endocrinology & Metabolism · doi:10.1586/eem.13.2 · Cited by 5
Effectiveness of Exenatide in Asian Indians in a Clinical Care Setting
Suthakaran, C., Fathima, M., Anjana, R. M., Ranjit Unnikrishnan, I., & Mohan, V. (2010) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2010.0033 · Cited by 5
Review: The evolving world of GLP-1 agonist therapies for type 2 diabetes
Baynes, K. (2010) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018810375414 · Cited by 6
Zhang, L. W., Tobin, G. A. M., & Rouse, R. L. (2012) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2012.08.008 · Cited by 8
Mohtadi, S., Molavinia, S., Shariati, S., Mahdavinia, M., Dayer, D., & Farzam, F. (2025) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.70584 · Cited by 5
Molecular engineering of designer diabetes therapeutics
DeWolf, E. L., Webber, B., & Webber, M. J. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.114705 · Cited by 5
Quan, N. V., Xuan, T. D., Anh, L. H., Cuc, D. T. K., & Khanh, T. D. (2024) · International Food Research Journal · doi:10.47836/ifrj.31.3.22 · Cited by 4
A New Therapy of Type 2 Diabetes: DPP-4 Inhibitors
Ábel, T. (2011) · InTech eBooks · doi:10.5772/23604 · Cited by 4
Perin, P. C., & Fornengo, P. (2011) · Internal and Emergency Medicine · doi:10.1007/s11739-011-0677-5 · Cited by 6
Perry, R. A., Craig, S. L., Gault, V. A., Flatt, P. R., & Irwin, N. (2021) · Bioscience Reports · doi:10.1042/bsr20211275 · Cited by 6
Tierney, K. (2012) · Journal of the American Academy of Nurse Practitioners · doi:10.1111/j.1745-7599.2012.00720.x · Cited by 6
Sharallah, O. A., Malakar, V. K., Salama, A. E., Elmaaz, S. M., Daba, S. A., & Poddar, N. K. (2026) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-026-01702-0 · Cited by 4
Oladghaffari, M., Rahnemayan, S., Tohid, Z., Montazer, M., & Oskouei, F. D. (2023) · International Journal of Drug Research in Clinics · doi:10.34172/ijdrc.2023.e19 · Cited by 5
Bauri, R., Bele, S. D., Edelli, J., Reddy, N. C., Kurukuti, S., Devasia, T., Ibrahim, A., Rai, V., & Mitra, P. (2024) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00474.2023 · Cited by 3
Clinical Trials on Diabetes Mellitus
Extremera, B. G., López, P. J., Ramírez, A. J. G., Peñalver, E. G., Martínez, M. L. A., & Fernández, I. M. (2015) · InTech eBooks · doi:10.5772/59130 · Cited by 3
Translational Endocrinology & Metabolism: Metabolic Surgery Update
DEL PRATO, S., & Lebovitz, H. E. (2012) · Translational endocrinology & metabolism · doi:10.1210/team.9781936704071 · Cited by 3
GLP-1 receptor agonists—another promising therapy for Alport syndrome?
Boeckhaus, J., Mabillard, H. R., & Sayer, J. A. (2025) · Journal of Rare Diseases · doi:10.1007/s44162-024-00065-8 · Cited by 4
Imam, N., Hussain, M. S., Hassan, M. N., Aziz, T., Naseem, N., Ahmad, M. F., Siddiqui, W. A., & Khan, R. H. (2025) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2025.09.015 · Cited by 4
Translational Research in Drug Discovery and Development
Arora, N., Maurya, P. K., & Kacker, P. (2017) · Translational medicine research · doi:10.1007/978-94-024-1045-7_3 · Cited by 11
New prospects in the treatment of diabetes mellitus
Шамхалова, М. Ш., Trubitsyna, N. P., & Shestakova, M. V. (2012) · Diabetes Mellitus · doi:10.14341/2072-0351-5547 · Cited by 3
Management of Unmet Needs in Type 2 Diabetes Mellitus: The Role of Incretin Agents
Goldenberg, R. (2011) · Canadian Journal of Diabetes · doi:10.1016/s1499-2671(11)80008-0 · Cited by 4
Arteaga, P. V., Hernández, M. L., & Alemán, J. A. (2013) · Atención Primaria · doi:10.1016/j.aprim.2012.12.013 · Cited by 3
Hanna, A., Woo, V. C., Yale, J., & Cooke, E. M. (2012) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2012.01.005 · Cited by 5
Liraglutide, the once-daily human GLP-1 analog, in the treatment of Type 2 diabetes
Hribal, M. L., & Sesti, G. (2010) · Expert Review of Endocrinology & Metabolism · doi:10.1586/eem.10.20 · Cited by 3
Pathogenesis of Type 2 Diabetes—A Comprehensive Analysis
Unger, J. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-385083-6.00003-6 · Cited by 3
Toxicology Assessment of a Dual-Function Peptide 5rolGLP-HV in Mice
Ni, Z., Wang, B., Ma, X., Duan, H., Jiang, P., Li, X., Wei, Q., Ji, X., & Li, M. (2016) · Applied Biochemistry and Biotechnology · doi:10.1007/s12010-016-2166-9 · Cited by 3
An up-to-date evaluation of alogliptin benzoate for the treatment of type 2 diabetes
Hu, J., Yang, C., Wang, H., Li, J., Tan, X., Wang, J., Zhang, B., & Zhao, Y. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1645124 · Cited by 3
Update on the Management of Diabetes during Ramadan Fast for Healthcare Practitioners
Rathor, M. Y., Mohammed Fauzi, A. R., & Omar, A. M. (2014) · IIUM Medical Journal Malaysia · doi:10.31436/imjm.v13i2.482 · Cited by 3
Arba, M., Ruslin, R., AKIB, N. I., Yamin, Y., Ombe, S., Jessi, J., Muzakkar, M. Z., & Tjahjono, D. H. (2018) · Journal of Applied Pharmaceutical Science · doi:10.7324/japs.2018.81001 · Cited by 3
Baek, J. G., Park, D. H., Vu, N. K., Muvva, C., Hwang, H., Song, S., Lee, H., Kim, T., Kwon, H. C., Park, K., et al. (2024) · Plants · doi:10.3390/plants13050608 · Cited by 2
[A useful guide for selecting pharmacotherapy in type 2 diabetes].
Zárate, A., Basurto, L., Saucedo, R., & Hernández-Valencia, M. (2010) · PubMed · Cited by 2
Exenatide-Induced Acute Renal Failure: A Case Report
Ünübol, M., Gencer, F., Akdam, H., Yeniçerioğlu, Y., Akar, H., & Güney, E. (2013) · Endocrinology research and practice. · doi:10.4274/tjem.2259 · Cited by 2
Liraglutide pour le traitement du diabète de type 2
Avignon, A., & Sauvanet, J.-P. (2010) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(10)70066-3 · Cited by 2
Menéndez, S. A. (2010) · Atención Primaria · doi:10.1016/s0212-6567(10)70005-6 · Cited by 2
Efficacy and safety of sitagliptin in J apanese patients with type 2 diabetes switched from glinides
Tanaka, T., Goto, H., Araki, R., Yamamoto, M., Tanaka, T., Fujiwara, R., & Murata, K. (2013) · Journal of Diabetes Investigation · doi:10.1111/jdi.12140 · Cited by 2
Myers, A. K., Garnica, P., & Ling, J. (2018) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000000667 · Cited by 5
Biosynthesis, Processing, and Secretion of the Islet Hormones
Steiner, D. F., Rhodes, C. J., Philipson, L. H., Bell, G. I., & Chan, S. J. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-18907-1.00031-7 · Cited by 3
Cheng, C., Masoud, J. A., McCray, E., Sun, C., & Momodu, I. (2021) · Gastroenterology Nursing · doi:10.1097/sga.0000000000000602 · Cited by 2
A Short Review on Anti-diabetics for Uncontrolled Type 2 Diabetes Mellitus
Ahmad, H., & Chowdhury, M. A. N. (2019) · Medicine Today · doi:10.3329/medtoday.v31i2.41966 · Cited by 2
Lee, S. P., Kuo, F. Y., Cheng, J., & Wu, M. C. (2019) · Archives of Medical Science · doi:10.5114/aoms.2019.86938 · Cited by 5
Place in Therapy for Liraglutide and Saxagliptin for Type 2 Diabetes
McFarland, M. S., Brock, M., & Ryals, C. (2011) · Southern Medical Journal · doi:10.1097/smj.0b013e318215fc7a · Cited by 2
Ghosh, K., & Sobhia, M. E. (2022) · Research Square · doi:10.21203/rs.3.rs-1721735/v1 · Cited by 2
Mamontova, E. D., Michurina, S. S., Стафеев, Ю. С., Sorkina, E., Скляник, И. А., Koksharova, E., Menshikov, M., Shestakova, M. V., & Парфёнова, Е. В. (2021) · Biochemistry (Moscow) · doi:10.31857/s032097252103009x · Cited by 1
Risk of pancreatic cancer associated with GLP-1 receptor agonist therapy
Krishna, S., Dungan, K. M., Shah, R., Cruz‐Monserrate, Z., DelGiorno, K. E., Tan, M., & Hart, P. A. (2026) · npj gut and liver. · doi:10.1038/s44355-026-00069-9 · Cited by 1
Vaciamiento gástrico y Diabetes mellitus tipo 2
Cadavid, C. A. Q., Regino, W. O., & Vega, R. F. (2015) · Revista de la Facultad de Medicina · doi:10.15446/revfacmed.v63n2.46195 · Cited by 2
Raza, S. A., & Hassan, M. (2013) · Journal of the ASEAN Federation of Endocrine Societies · doi:10.15605/jafes.028.01.05 · Cited by 1
Incretin-Based Therapy and Pancreatitis—What is the Risk?
Sternthal, E. (2011) · Endocrine Practice · doi:10.4158/ep.17.3.334 · Cited by 1
The Incretin System and Cardiovascular Risk: Effects of Incretin-Targeted Therapies
Mundil, D., Noyan-Ashraf, M. H., & Husain, M. (2010) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-010-0141-5 · Cited by 1
Ahluwalia, R., & Vora, J. P. (2012) · The British Journal of Diabetes · doi:10.1177/1474651411431846 · Cited by 1
Hypoglycaemia Fear among Diabetics
Omar, S., Albsoul, A., & Alabbadi, I. (2016) · Jordan Journal of Pharmaceutical Sciences · Cited by 2
Use of Non-insulin Agents for Hyperglycemia Management in Hospitalized Patients
Harris, Y., Reich, D., & Li, X. Q. (2023) · Contemporary Endocrinology · doi:10.1007/978-3-031-44648-1_6 · Cited by 1
Regulation of glucose metabolism by incretins: implications for treatment of type 2 diabetes
Saito, R., & Harada, N. (2024) · Diabetology International · doi:10.1007/s13340-024-00781-y · Cited by 2
Zhao, D., Zhao, S., Wang, X., Su, M., Liu, W., Ma, Q., Hong, J., Gu, W., Li, J., Liu, R., et al. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00062 · Cited by 1
Damayanti, D. S., Nurdiana, N., KUSUMA, M. C., & Soeatmadji, D. W. (2019) · International Journal of Applied Pharmaceutics · doi:10.22159/ijap.2019.v11s6.33549 · Cited by 2
Bussière, C., Chauvin, P., Josselin, J., & Sevilla‐Dedieu, C. (2022) · Health Economics Review · doi:10.1186/s13561-022-00397-5 · Cited by 1
Cani, C. G. (2011) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.5.2011.tde-24082011-161031 · Cited by 1
Exploring the structure, function & regulation of the human glucagon-like peptide-1 receptor
Huang, Y. (2011) · OpenGrey (Institut de l'Information Scientifique et Technique) · Cited by 2
Advances in the management of type 2 diabetes mellitus
Moustafa, N. (2012) · The Egyptian Journal of Internal Medicine · doi:10.7123/01.ejim.0000418015.54092.98 · Cited by 1
Efficacy of Tirzepatide for Weight Loss in China: Implications for the Global Obesity Epidemic
Qian, F., & Hu, F. B. (2024) · JAMA · doi:10.1001/jama.2024.7928 · Cited by 1
Is there a Role for Incretin‐Based Therapy in Combination with Insulin?
Sathananthan, M., & Vella, A. V. (2011) · doi:10.1002/9781444340280.ch10
Glycemic treatment of diabetes mellitus
Kaur, H., & Weinstock, R. S. (2014) · Wiley eBooks · doi:10.1002/9781118887837.ch4
De behandeling van diabetes: stap voor stap
Reenders, K., Tavenier, D., & Woudstra, J. G. (2010) · Bijblijven · doi:10.1007/bf03088748
Management of type 2 diabetes mellitus for general practitioners
Klisiewicz, A., & Huddle, K. (2011) · Journal of Endocrinology Metabolism and Diabetes of South Africa · doi:10.1080/22201009.2011.10872255
Incretin System: Recent Advances in Glucagon Like Peptide-1 and Dipeptidyl Peptidase-4 Inhibitors
Mahaseth, R. (2015) · Journal of Patan Academy of Health Sciences · doi:10.3126/jpahs.v1i1.13015 · Cited by 1
Extrapancreatic actions of incretin-based therapies on bone in diabetes mellitus
Mansur, S. A. (2015) · UTHM Institutional Repository (Universiti Tun Hussein Onn Malaysia)
Whey protein: Effects on insulin secretion and intestinal health via intestinal peptides
Ney, D. M., & Boehler, C. J. (2011) · Nutrafoods · doi:10.1007/bf03223384
Assessing Risks of Glucose Lowering Therapy in Heart Failure: Should We Rely on Post-hoc Analyses?
Hsu, J. J., & Fonarow, G. C. (2016) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-016-0486-5 · Cited by 1
Merchant, C. E. (2011) · cIRcle (University of British Columbia) · doi:10.14288/1.0105089
Paulo, S., & Girardi, C. (2015)
Protein kinase STK25 is a regulator of hepatic lipid partitioning and whole body metabolism
Amrutkar, M. (2016) · Gothenburg University Publications Electronic Archive (Gothenburg University)
ACUTE PANCREATITIS ASSOCIATED WITH EXENATIDE AND LIRAGLUTIDE: A META-ANALYSIS
Alves, C., Marques, F. B., & Macedo, A. F. (2012) · Revista portuguesa de farmacoterapia · doi:10.25756/rpf.v4i3.66
Gokhale, M. (2016) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/athz-m068
ACUTE PANCREATITIS; FREQUENCY IN DIABETIC PATIENTS TAKING COMBINATION OF SITAGLIPTIN AND METFORMIN
Bashir, H. B., & Zubair, Z. (2017) · The Professional Medical Journal · doi:10.17957/tpmj/17.4022
Hepatitis C–Associated Diabetes Mellitus
Bilić-Čurčić, I., Roguljić, H., Ivandić, M., Včev, A., Smolić, R., & Smolić, M. (2017) · InTech eBooks · doi:10.5772/intechopen.70721
STK25- a new key regulator of metabolic profile and a possible target for anti-diabetic drug
Nuñez‐Durán, E. (2017) · Gothenburg University Publications Electronic Archive (Gothenburg University)
Antidiabetic properties of centella asiatica in type II diabetic rats.
Oyenihi, A. B. (2016) · ResearchSpace (University of KwaZulu-Natal)
Mitkova, Z. E., Mitov, K., Valov, V., Manova, M. M., Savova, A., Kamusheva, M., Tcharaktchiev, D., Angelov, Z., Angelova, G., & Petrova, G. I. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00364
Insight in disease and drug interactions, with treatment optimisation of patients with cancer
Knapen (2019) · Research Publications (Maastricht University) · doi:10.26481/dis.20190510lk
Thérapeutique des désordres glycémiques
Monnier, L., & Colette, C. (2014) · Elsevier eBooks · doi:10.1016/b978-2-294-73954-5.00007-x
Metadata
- Authors
- Drucker, D. J., Sherman, S. I., Gorelick, F. S., Bergenstal, R. M., Sherwin, R. S., & Buse, J. B.
- Affiliations
- University of Toronto (CA)
- The University of Texas MD Anderson Cancer Center (US)
- Yale University (US)
- Park Nicollet Health Services (US)
- University of North Carolina at Chapel Hill (US)
- Corresponding author
- Drucker, Daniel J.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2010-02-01
- Volume
- 33
- Issue
- 2
- Pages
- 428-433
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC2809297
- OpenAlex
- W2134760433
- Cited by
- 316
- References
- 40
- Citations by year
- 2026: 10 · 2025: 10 · 2024: 10 · 2023: 10 · 2022: 13 · 2021: 15 · 2020: 11 · 2019: 17 · 2018: 17 · 2017: 15 · 2016: 20 · 2015: 24 · 2014: 28 · 2013: 33 · 2012: 31
- FWCI
- 28.47
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- V Foundation for Cancer Research
- Park Nicollet Foundation
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Celgene
- F. Hoffmann-La Roche
- Exelixis
- Insulet Corporation
- MannKind Corporation
- ResMed
- Eisai
- Novo Nordisk
- Plexxikon
- National Institutes of Health
- National Cancer Institute
- National Institute of Diabetes and Digestive and Kidney Diseases (T32DK007017)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- type 2 diabetes, incretin-based therapy, GLP-1 receptor agonists, DPP-4 inhibitors, glycemic control, insulin resistance, insulin secretion, diabetes complications, drug safety, obesity
- MeSH terms
- Exenatide, Diabetes Mellitus, Type 2, Drug Administration Schedule, Humans, Hypoglycemic Agents, Peptides, Venoms, Incidence, Prevalence, Treatment Outcome, Risk Assessment, Glucagon-Like Peptide 1, Incretins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.